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2007-2008 Influenza Season 
Week 15, ending April 12, 2008 
 (All data are preliminary and may change as more reports are received.) 
 
Synopsis:  During week 15 (April 6 – 12, 2008), influenza activity continued to decrease in the 
United States.   
o Three hundred fifty (11.9%) specimens tested by U.S. World Health Organization (WHO) 
and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating 
laboratories were positive for influenza. 
o The proportion of deaths attributed to pneumonia and influenza has been above the 
epidemic threshold for 14 consecutive weeks. 
o The proportion of outpatient visits for influenza-like illness (ILI) and the proportion of 
outpatient visits for acute respiratory illness (ARI) were below national baseline levels. ILI 
was above the region-specific baseline in one region (New England), while the proportion of 
outpatient visits reported for ARI was below all region and age-specific baselines.   
o Three states reported widespread influenza activity; four states reported regional influenza 
activity; 16 states reported local influenza activity; 26 states and the District of Columbia and 
Puerto Rico reported sporadic influenza activity; and one state reported no influenza activity.  
 
National and Regional Summary of Select Surveillance Components 
  Data for current week Data cumulative for the season 
  
Sentinel 
Provider 
ILI* 
DoD and 
VA ARI* 
% pos. 
for flu†
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity‡  
A 
(H1) 
A 
(H3) 
A 
Unsub-
typed 
B Pediatric Deaths 
Nation Normal Normal 11.9% 7 of 51  2127 5705 18166 9487 66 
New 
England Elevated Normal 13.6% 3 of 6 94 183 954 960 7 
Mid-
Atlantic Normal Normal 23.0% 3 of 3 209 344 1173 1338 12 
East North 
Central Normal Normal 17.4% 0 of 5 178 1323 612 540 8 
West 
North 
Central Normal Normal 18.1% 0 of 7 104 192 2739 1447 6 
South 
Atlantic Normal Normal 13.3% 0 of 9 344 1749 4651 1559 7 
East 
South 
Central Normal Normal 14.2% 0 of 4 37 756 144 132 6 
West South 
Central Normal Normal 7.2% 0 of 4 109 497 5981 1693 8 
Mountain Normal Normal 10.7% 0 of 8 526 446 983 1046 5 
Pacific Normal Normal 12.8% 1 of 5 526 215 929 772 7 
* Elevated means the % of visits for ILI or ARI is at or above the national or region-specific baseline 
† National data are for current week; regional data are for the most recent three weeks 
‡ Includes all 50 states and the District of Columbia 
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Laboratory Surveillance:  During week 15, WHO and NREVSS laboratories reported 2,935 
specimens tested for influenza viruses, 350 (11.9%) of which were positive, including five influenza 
A (H1) viruses, 24 influenza A (H3) viruses, 105 influenza A viruses that were not subtyped, and 
216 influenza B viruses.   
 
Since September 30, 2007, WHO and NREVSS laboratories have tested a total of 192,828 
specimens for influenza viruses and 35,485 (18.4%) were positive. Among the 35,485 influenza 
viruses, 25,998 (73.3%) were influenza A viruses and 9,487 (26.7%) were influenza B viruses.  
Seven thousand eight hundred thirty-two (30.1%) of the 25,998 influenza A viruses have been 
subtyped: 2,127 (27.2%) were influenza A (H1) viruses and 5,705 (72.8%) were influenza A (H3) 
viruses. 
 
During the 2007-08 season, influenza A (H1), A (H3), and B viruses have co-circulated in the United 
States.  Influenza A (H3) viruses have predominated during the season overall, however, the most 
commonly reported influenza virus has varied by week.  From week 40 through week 3 (September 
30, 2007 – January 19, 2008) influenza A (H1) viruses were more frequently reported; from week 4 
through week 12 (January 20 – March 22, 2008), influenza A (H3) viruses were more commonly 
reported; and from weeks 13 through 15 (March 23 – April 12, 2008), more influenza B than 
influenza A viruses were reported.  The predominant virus has also varied by region.  Influenza A 
(H3) viruses have been reported more frequently than A (H1) viruses in seven of the nine 
surveillance regions (East North Central, East South Central, Mid-Atlantic, New England, South 
Atlantic, West North Central, and West South Central) while influenza A (H1) viruses have 
predominated this season in two regions (Mountain and Pacific). 
U.S. WHO/NREVSS Collaborating Laboratories
National Summary, 2007-08
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Composition of the 2008-09 Influenza Vaccine:  WHO and FDA have recommended that the 
2008-09 trivalent influenza vaccine for the Northern Hemisphere contain A/Brisbane/59/2007-like 
(H1N1), A/Brisbane/10/2007-like (H3N2), and B/Florida/4/2006-like viruses.  All three components 
have been changed from the 2007-08 Northern Hemisphere vaccine formulation.  
A/Brisbane/10/2007-like (H3N2) and B/Florida/4/2006-like viruses are currently included in the 2008 
Southern Hemisphere vaccines.  This recommendation was based on surveillance data related to 
epidemiology and antigenic characteristics, serological responses to 2007-08 vaccines, and the 
availability of candidate strains and reagents. 
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Antigenic Characterization:  CDC has antigenically characterized 620 influenza viruses [290 
influenza A (H1N1), 161 influenza A (H3N2), and 169 influenza B viruses] collected by U.S. 
laboratories since September 30, 2007. 
 
Influenza A (H1N1) [290] 
• Two hundred (69%) of the 290 viruses were characterized as A/Solomon 
Islands/3/2006-like, the influenza A (H1N1) component of the 2007-08 influenza 
vaccine for the Northern Hemisphere and the 2008 influenza A (H1N1) component 
for the Southern Hemisphere. 
• Twenty (7%) of the 290 viruses showed somewhat reduced titers with antisera 
produced against A/Solomon Islands/3/2006. 
• Seventy (24%) of the 290 viruses were characterized as A/Brisbane/59/2007-like. 
A/Brisbane/59/2007 is a recent genetic/antigenic variant which evolved from 
A/Solomon Islands/03/2006. An A/Brisbane/59/2007-like virus is the WHO 
recommended strain for the 2008-09 Northern Hemisphere vaccine formulation. 
Influenza A (H3N2) [161] 
• Thirty-five (22%) of the 161 viruses were characterized as A/Wisconsin/67/2005-like, 
the influenza A (H3N2) component of the 2007-08 influenza vaccine for the Northern 
Hemisphere. 
• One hundred fifteen (71%) of the 161 viruses were characterized as 
A/Brisbane/10/2007-like.  A/Brisbane/10/2007-like viruses are a recent antigenic 
variant which evolved from, but are antigenically distinct from, A/Wisconsin/67/2005-
like viruses.  A/Brisbane/10/2007-like virus is the recommended influenza A (H3N2) 
component for the 2008 Southern Hemisphere and 2008-09 Northern Hemisphere 
vaccines. 
• Eleven (7%) of the 161 viruses showed somewhat reduced titers with antisera 
produced against A/Wisconsin/67/2005 and A/Brisbane/10/2007. 
 
Influenza B (B/Victoria/02/87 and B/Yamagata/16/88 lineages) [169] 
Victoria lineage [8] 
• Eight (5%) of the 169 influenza B viruses characterized belong to the B/Victoria 
lineage of viruses. 
o Six (75%) of these 8 viruses were characterized as B/Ohio/01/2005-like. The 
recommended influenza B component for the 2007-08 influenza vaccine is a 
B/Malaysia/2506/2004-like virus, belonging to the B/Victoria lineage.  
B/Ohio/01/2005 is a recent B/Malaysia/2506/2004-like reference strain. 
o Two (25%) of these 8 viruses showed somewhat reduced titers with antisera 
produced against B/Ohio/01/2005 and B/Malaysia/2506/2004.  
Yamagata lineage [161] 
• One hundred sixty-one (95%) of the 169 influenza B viruses characterized belong to 
the B/Yamagata lineage of viruses.   
o One hundred fifty-six (97%) of these 161 viruses were identified as 
B/Florida/04/2006-like, the recommended influenza B component for the 
2008-09 Northern Hemisphere vaccine formulation. 
o Five (3%) of these 161 viruses showed a somewhat reduced titer with 
antiserum produced against B/Florida/04/2006.  
 
These data indicate similarities and differences between a sample of circulating strains and this 
year's vaccine strains as determined by laboratory studies. Interim results from a study carried out 
with the Marshfield Clinic in Wisconsin found vaccine effectiveness of 58% against circulating 
influenza A (H3N2) viruses, based on data collected from Jan 21 through Feb 8, 2008. No vaccine 
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effectiveness against influenza B viruses was found.  No influenza A (H1N1) viruses were identified 
through Feb 8 and, thus, no vaccine effectiveness estimate is available for H1N1 viruses.  These 
interim results suggest that vaccination provided substantial protection against H3N2 influenza-
associated medically attended illness in the study population. Enrollment in this study concluded on 
March 28, 2008, and final results will be available later this year.  Additional information on this 
study can be found at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5715a1.htm 
 
Antiviral Resistance: In the United States, two groups of antiviral drugs have been approved by 
FDA for use in treating or preventing influenza virus infections.  These two groups of antiviral drugs 
are: neuraminidase inhibitors (oseltamivir and zanamivir) and adamantanes (amantadine and 
rimantadine). A description of these drugs can be found at: 
http://www.cdc.gov/flu/protect/antiviral/index.htm.  
 
Neuraminidase Inhibitor Antiviral Drugs:  So far this season, 1,195 influenza A and B 
viruses from the United States have been tested for antiviral resistance.  Eighty-seven 
(8.3%) of 1,048 influenza A viruses tested, and 0 (0.0%) of 147 influenza B viruses tested 
have been found to be resistant to oseltamivir.  Currently all of the resistant viruses are 
influenza A (H1N1) viruses, with 87 (10.4%) of 838 influenza A (H1N1) viruses tested 
exhibiting a genetic mutation that confers oseltamivir resistance.  All tested viruses retain 
their sensitivity to zanamivir.  Additional information on antiviral resistance can be found at: 
http://www.cdc.gov/flu/about/qa/antiviralresistance.htm 
 
Adamantane Antiviral Drugs: Resistance to the adamantanes continues to be high among 
influenza A (H3N2) viruses with 278 (99.6%) of 279 influenza A (H3N2) viruses tested 
resistant to the adamantanes.  Adamantane resistance among influenza A (H1N1) viruses 
has also been detected but at a lower level. Of 755 influenza A (H1N1) viruses tested, 83 
(11.0%) were resistant to the adamantanes.  The adamantanes are not effective against 
influenza B viruses.  Since late January, influenza A (H3N2) viruses have predominated in 
the United States, and during week 14, 72.8% of influenza A viruses subtyped were A 
(H3N2).  
 
Based on the level of oseltamivir resistance observed in only one influenza subtype, H1N1, 
persisting high levels of resistance to the adamantanes in H3N2 viruses, and the 
predominance of H3N2 viruses circulating in the United States during the 2007-08 season 
with co-circulation of influenza B viruses, CDC continues to recommend the use of 
oseltamivir and zanamivir for the treatment or prevention of influenza.  Use of amantadine or 
rimantadine is not recommended.  Guidance on influenza antiviral use can be found at: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5606a1.htm 
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Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 15, 7.8% of all deaths 
reported through the 122 Cities Mortality Reporting System were reported as due to P&I. This 
percentage is above the epidemic threshold of 6.8% for week 15.  Including week 15, P&I mortality 
has been above epidemic threshold for 14 consecutive weeks. 
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Influenza-Associated Pediatric Mortality: One influenza-associated pediatric death was reported 
to CDC during week 15 (FL).  This death occurred during week 11 (March 9-15, 2008).  Since 
September 30, 2007, CDC has received a total of 66 reports of influenza-associated pediatric 
deaths that occurred during the current season.   
Number of Influenza-Associated Pediatric Deaths
by Week of Death:
2005-06 season to present
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Influenza-Associated Pediatric Hospitalizations:  Laboratory-confirmed influenza-associated 
pediatric hospitalizations are monitored in two population-based surveillance networks: the New 
Vaccine Surveillance Network (NVSN) and the Emerging Infections Program (EIP).  These two 
systems provide updates of surveillance data every two weeks.  As a result of differing dates for 
initiating surveillance in the 2007-08 season, these updates occur on alternating weeks.  
During November 4, 2007, to April 5, 2008, the preliminary laboratory-confirmed influenza-
associated hospitalization rate for children 0-4 years old in the NVSN was 6.78 per 10,000. 
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During September 30 – March 29, 2008, the preliminary laboratory-confirmed influenza-associated 
hospitalization rate reported by the EIP for children 0–17 years old was 1.32 per 10,000.  For 
children aged 0-4 years and 5-17 years, the rate was 3.47 per 10,000 and 0.45 per 10,000, 
respectively.  
EIP Influenza Laboratory-Confirmed Cumulative Hospitalization Rates 
for Children Aged 0-4 and 5-17 yrs, 2007-2008 and Previous 4 Seasons
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Outpatient Illness Surveillance:  Nationwide during week 15, 1.5% of outpatient visits reported 
through the U.S. Influenza Sentinel Provider Surveillance Network were due to influenza-like illness 
(ILI), which was below the national baseline of 2.2%.  On a regional level, the percentage of 
outpatient visits for ILI ranged from 0.7% to 3.0%.  One region (New England) reported ILI above its 
region-specific baseline, while the remaining eight regions (East North Central, East South Central, 
Mid-Atlantic, Mountain, Pacific, South Atlantic, and West North Central, and West South Central) 
reported ILI below their region-specific baselines. 
During week 15, 2.1% of patient visits to Department of Veteran’s Affairs (VA) and Department of 
Defense (DoD) outpatient treatment facilities were for acute respiratory illness (ARI), which was 
below the national baseline of 3.2%.  On a regional level, the percentage of visits for ARI ranged 
from 1.2% to 2.5%, and was below region-specific baselines in all nine regions.  All five age groups 
reported ARI below their age-specific baselines.   
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Percentage of Visits for ILI & ARI Reported
by Sentinel Providers and BioSense Outpatient Facilities,
National Summary
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Percentage of Visits for ARI by Age Group Reported by 
DoD/VA Outpatient Clinics - National Summary
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: During 
week 15 the following influenza activity was reported: 
• Widespread activity was reported by three states (Connecticut, New York, and 
Pennsylvania). 
• Regional activity was reported by four states (Alaska, Maine, New Hampshire, and New 
Jersey). 
• Local influenza activity was reported by 16 states (Arizona, Georgia, Florida, Hawaii, Idaho, 
Illinois, Massachusetts, Montana, North Dakota, Oregon, Rhode Island, South Carolina, 
Texas, Utah, Vermont, and Washington). 
• Sporadic influenza activity was reported by the District of Columbia, Puerto Rico, and 26 
states (Alabama, Arkansas, California, Colorado, Delaware, Indiana, Iowa, Kansas, 
Kentucky, Louisiana, Maryland, Michigan, Minnesota, Mississippi, Missouri, Nebraska, 
Nevada, New Mexico, Ohio, Oklahoma, South Dakota, Tennessee, Virginia, West Virginia, 
Wisconsin, and Wyoming). 
• No influenza activity was reported by one state (North Carolina). 
 
 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: April 18, 2008
